Control Bionics (ASX:CBL) Common Stock: A$46.15 Mil (As of Dec. 2025)


What is Control Bionics Common Stock?

Control Bionics ASX:CBL +3.47% Common Stock is A$46.15 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

Control Bionics's quarterly common stock increased from Dec. 2024 (A$38.40 Mil) to Jun. 2025 (A$40.37 Mil) and increased from Jun. 2025 (A$40.37 Mil) to Dec. 2025 (A$46.15 Mil).

Control Bionics's annual common stock increased from Jun. 2023 (A$30.24 Mil) to Jun. 2024 (A$35.15 Mil) and increased from Jun. 2024 (A$35.15 Mil) to Jun. 2025 (A$40.37 Mil).

Control Bionics Common Stock Historical Data

* Premium members only.

The historical data trend for Control Bionics's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Control Bionics Common Stock Chart

Control Bionics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Common Stock
Get a 7-Day Free Trial 28.18 29.27 30.24 35.15 40.37

Control Bionics Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.04 35.15 38.40 40.37 46.15

Control Bionics Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of A$46.15 Mil mean?
Control Bionics (ASX:CBL) has a Common Stock of A$46.15 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Control Bionics and its competitors.
Is Control Bionics' Common Stock too high?
Control Bionics' current Common Stock is A$46.15 Mil.
How does Control Bionics' Common Stock compare to ABT and SYK?
Control Bionics' Common Stock of A$46.15 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Medical Devices & Instruments company?
A good Common Stock depends on the Medical Devices & Instruments industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Control Bionics and its competitors. Control Bionics's current Common Stock is A$46.15 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.07 — trading 148.3% above its estimated fair value. The current Common Stock is A$46.15 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current Common Stock is A$46.15 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Control Bionics Business Description

Address 11-13 Pearson Street, Level 4, Cremorne, VIC, AUS, 3121
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.